CY1119145T1 - Μεθοδοι για αγωγη ανοσιακων διαταραχων που συσχετιζονται με μεταμοσχευση μοσχευματων με ευδιαλυτα μορια μεταλλαγματων toy ctla4 - Google Patents
Μεθοδοι για αγωγη ανοσιακων διαταραχων που συσχετιζονται με μεταμοσχευση μοσχευματων με ευδιαλυτα μορια μεταλλαγματων toy ctla4Info
- Publication number
- CY1119145T1 CY1119145T1 CY20171100812T CY171100812T CY1119145T1 CY 1119145 T1 CY1119145 T1 CY 1119145T1 CY 20171100812 T CY20171100812 T CY 20171100812T CY 171100812 T CY171100812 T CY 171100812T CY 1119145 T1 CY1119145 T1 CY 1119145T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- ctla4
- soluble
- toi
- translators
- Prior art date
Links
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 title abstract 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 title abstract 3
- 208000026278 immune system disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 108010035053 B7-1 Antigen Proteins 0.000 abstract 1
- 102000038504 B7-1 Antigen Human genes 0.000 abstract 1
- 102000007697 B7-2 Antigen Human genes 0.000 abstract 1
- 108010021800 B7-2 Antigen Proteins 0.000 abstract 1
- 238000005520 cutting process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Alternative & Traditional Medicine (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66877405P | 2005-04-06 | 2005-04-06 | |
| PCT/US2006/012648 WO2006108035A1 (en) | 2005-04-06 | 2006-04-05 | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119145T1 true CY1119145T1 (el) | 2018-02-14 |
Family
ID=36694299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100812T CY1119145T1 (el) | 2005-04-06 | 2017-07-28 | Μεθοδοι για αγωγη ανοσιακων διαταραχων που συσχετιζονται με μεταμοσχευση μοσχευματων με ευδιαλυτα μορια μεταλλαγματων toy ctla4 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7482327B2 (https=) |
| EP (1) | EP1868635B1 (https=) |
| JP (1) | JP2008535841A (https=) |
| KR (1) | KR101235484B1 (https=) |
| CN (1) | CN101198347A (https=) |
| AR (1) | AR055052A1 (https=) |
| AU (1) | AU2006231622B2 (https=) |
| BR (1) | BRPI0608144A2 (https=) |
| CA (1) | CA2603970A1 (https=) |
| CY (1) | CY1119145T1 (https=) |
| DK (1) | DK1868635T3 (https=) |
| EA (1) | EA013122B1 (https=) |
| ES (1) | ES2634260T3 (https=) |
| HR (1) | HRP20171121T8 (https=) |
| IL (1) | IL186189A (https=) |
| LT (1) | LT1868635T (https=) |
| ME (1) | ME02930B (https=) |
| MX (1) | MX2007012222A (https=) |
| NO (1) | NO342966B1 (https=) |
| NZ (2) | NZ561655A (https=) |
| PL (1) | PL1868635T3 (https=) |
| PT (1) | PT1868635T (https=) |
| RS (1) | RS56138B1 (https=) |
| SI (1) | SI1868635T1 (https=) |
| WO (1) | WO2006108035A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| BRPI0608144A2 (pt) * | 2005-04-06 | 2009-11-17 | Bristol Myers Squibb Co | uso de uma molécula mutante de ctla4 |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
| WO2008014035A2 (en) * | 2006-07-25 | 2008-01-31 | The Regents Of The University Of California | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection |
| AU2008319053B2 (en) | 2007-11-01 | 2012-04-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
| WO2010098788A2 (en) * | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| EP2365823B1 (en) * | 2008-10-30 | 2016-11-30 | Yeda Research And Development Company Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| WO2010132891A1 (en) * | 2009-05-15 | 2010-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Combination therapy to inhibit t cell effector function |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| CN106432474A (zh) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| MX357746B (es) | 2010-09-08 | 2018-07-23 | Yeda Res And Development Co Ltd Star | Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma. |
| KR20130105652A (ko) | 2010-09-08 | 2013-09-25 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 안정하고 장기간의 인그래프트먼트를 위한 면역억제 약물의 조합 |
| AU2012305931B2 (en) | 2011-09-08 | 2017-09-07 | Yeda Research And Development Co. Ltd | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| BR112015024516A2 (pt) * | 2013-03-28 | 2017-10-24 | Bristol Myers Squibb Co | métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação |
| CN104673822A (zh) * | 2013-11-27 | 2015-06-03 | 深圳先进技术研究院 | 一种重组载体及其制备方法和应用 |
| CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
| EA201691634A1 (ru) | 2014-03-19 | 2016-11-30 | Бристол-Маерс Сквибб Компани | Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| JP7057748B2 (ja) | 2015-07-16 | 2022-04-20 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | 遺伝子改変された抗第三者中枢性メモリーｔ細胞および免疫療法におけるその使用 |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| CN110392736A (zh) | 2017-01-18 | 2019-10-29 | 耶达研究及发展有限公司 | 遗传修饰的反抑细胞及其在免疫治疗中的用途 |
| US10286036B2 (en) | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| EP3809983B1 (en) | 2018-06-22 | 2025-08-27 | Mayo Foundation for Medical Education and Research | Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality |
| WO2020010259A1 (en) * | 2018-07-06 | 2020-01-09 | Mayo Foundation For Medical Education And Research | Methods and materials for improving transplant outcomes |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CN115089718B (zh) * | 2021-11-30 | 2024-05-28 | 杭州瑞普晨创科技有限公司 | 用于异种移植的免疫抑制剂组合和免疫抑制方法 |
| KR102929448B1 (ko) | 2023-02-03 | 2026-02-26 | 이뮤노바이옴 주식회사 | 이식 거부 반응의 예방 또는 치료용 조성물 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| AU2002243905B2 (en) * | 2001-01-26 | 2007-11-08 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| MXPA03010568A (es) * | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles. |
| WO2003088991A1 (en) * | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| CN101857851A (zh) | 2002-12-23 | 2010-10-13 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法 |
| DE60335024D1 (de) | 2002-12-23 | 2010-12-30 | Bristol Myers Squibb Co | Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| BRPI0608144A2 (pt) * | 2005-04-06 | 2009-11-17 | Bristol Myers Squibb Co | uso de uma molécula mutante de ctla4 |
-
2006
- 2006-04-05 BR BRPI0608144-4A patent/BRPI0608144A2/pt not_active Application Discontinuation
- 2006-04-05 CA CA002603970A patent/CA2603970A1/en not_active Abandoned
- 2006-04-05 WO PCT/US2006/012648 patent/WO2006108035A1/en not_active Ceased
- 2006-04-05 ME MEP-2017-162A patent/ME02930B/me unknown
- 2006-04-05 NZ NZ561655A patent/NZ561655A/en not_active IP Right Cessation
- 2006-04-05 DK DK06749324.7T patent/DK1868635T3/en active
- 2006-04-05 PL PL06749324T patent/PL1868635T3/pl unknown
- 2006-04-05 CN CNA2006800198976A patent/CN101198347A/zh active Pending
- 2006-04-05 SI SI200632175A patent/SI1868635T1/sl unknown
- 2006-04-05 MX MX2007012222A patent/MX2007012222A/es active IP Right Grant
- 2006-04-05 HR HRP20171121TT patent/HRP20171121T8/hr unknown
- 2006-04-05 ES ES06749324.7T patent/ES2634260T3/es not_active Expired - Lifetime
- 2006-04-05 KR KR1020077025644A patent/KR101235484B1/ko not_active Expired - Lifetime
- 2006-04-05 EP EP06749324.7A patent/EP1868635B1/en not_active Expired - Lifetime
- 2006-04-05 EA EA200702180A patent/EA013122B1/ru active IP Right Revival
- 2006-04-05 LT LTEP06749324.7T patent/LT1868635T/lt unknown
- 2006-04-05 JP JP2008505489A patent/JP2008535841A/ja active Pending
- 2006-04-05 PT PT67493247T patent/PT1868635T/pt unknown
- 2006-04-05 RS RS20170794A patent/RS56138B1/sr unknown
- 2006-04-05 AU AU2006231622A patent/AU2006231622B2/en not_active Expired
- 2006-04-06 US US11/399,666 patent/US7482327B2/en not_active Expired - Lifetime
- 2006-04-06 AR ARP060101377A patent/AR055052A1/es unknown
-
2007
- 2007-09-23 IL IL186189A patent/IL186189A/en active IP Right Grant
- 2007-10-09 NO NO20075078A patent/NO342966B1/no unknown
-
2008
- 2008-11-19 US US12/313,342 patent/US20100041602A1/en not_active Abandoned
-
2009
- 2009-04-21 NZ NZ576434A patent/NZ576434A/en not_active IP Right Cessation
-
2017
- 2017-07-28 CY CY20171100812T patent/CY1119145T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119145T1 (el) | Μεθοδοι για αγωγη ανοσιακων διαταραχων που συσχετιζονται με μεταμοσχευση μοσχευματων με ευδιαλυτα μορια μεταλλαγματων toy ctla4 | |
| DE602006019446D1 (de) | An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs | |
| CY1109649T1 (el) | Αντιγονα και συνθεσεις απο neisseria | |
| CY1118668T1 (el) | Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων | |
| MX2009008620A (es) | Un metodo para mejorar la respuesta de celulas t. | |
| CY1111629T1 (el) | Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων | |
| EP4276198A3 (en) | Nucleic acid synthesis and sequencing using tethered nucleoside triphosphates | |
| EP4538295A3 (en) | Antigen binding molecules and methods of use thereof | |
| CY1118880T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| BRPI0514982A (pt) | adjuvante de glicosilceramida para antìgenos de sacarìdeo | |
| CY1115831T1 (el) | Απαλοιφες στον τομεα ii εξωτοξινης a pseudomonas που μειωνουν την μη ειδικη τοξικοτητα | |
| BRPI0708344B8 (pt) | vetores adenovirais quiméricos e composição imunogênica | |
| LTPA2018502I1 (lt) | Per burną vartojamos kladribino kompozicijos | |
| PL2135881T3 (pl) | Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu | |
| PE20081392A1 (es) | Moleculas de enlace de lingo | |
| EP1594536A4 (en) | ADJUVANT INFLUENZA VACCINE | |
| BRPI0520330A2 (pt) | adjuvante a base de ácido polinosìnico-policitidìlico | |
| MX2009008918A (es) | Activacion de celulas que presentan antigeno humano a traves de clec-6. | |
| CY1118710T1 (el) | Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης | |
| AR083295A1 (es) | Metodo para activar celulas t auxiliares | |
| ATE552276T1 (de) | Modifizierter anti-cd52-antikörper | |
| MA43794A (fr) | Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie | |
| ATE395082T1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
| BR0314373A (pt) | Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico | |
| BRPI0919236A8 (pt) | Terapêutica e vacinas de combinação de gas |